Overview

Docetaxel and Irinotecan in Gastric Cancer

Status:
Recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

To assess the role of docetaxel and irinotecan combination in second line gastric cancer. The primary end point is response rate. Secondary end points are toxicity, PFS and OS.

Phase:

Phase 2

Details

Lead Sponsor:

Menoufia University

Treatments:

Docetaxel
Irinotecan